Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gefitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 18/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 2/20 | 1.00 |
| ▸ | FLT4 | P35916 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gefitinib SCHEMBL7866 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| SCHEMBL1734701 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351336 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29351046 | 1.00 | EGFR (1.00) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28098790 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL29371159 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL2770155 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL28097850 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL11776 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 | |
| Gefitinib SCHEMBL30887946 | 0.99 | EGFR (0.98) | EGFRKDRBRAFEPHB4FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100203043-A1 | TREATMENT AND DIAGNOSIS OF METASTATIC PROSTATE CANCER WITH INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) | PAMGENE B.V. (NL) | 2010-08-12 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | claimed |
| US-20040167139-A1 | Methods of treating cancer | INDIANA UNIVERSITY | 2004-08-26 | — | — | US | claimed |
| WO-2004010937-A2 | METHOD OF TREATING CANCER | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE AT INDIANA UNIVERSITY (US) | 2004-02-05 | — | — | WO | claimed |
| EP-4346777-A1 | FORMIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | Lonza Bend Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230414515-A1 | ACETIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | LONZA BEND INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4221692-A1 | ACETIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | Lonza Bend Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022254033-A1 | FORMIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | BEND RESEARCH, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-11364297-B2 | Photosensitizing antibody-fluorophore conjugates | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| US-11364298-B2 | Photosensitizing antibody-fluorophore conjugates | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| CN-113257108-A | Device and method for direct drug infusion | 基因泰克股份有限公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2005016241-A2 | SYNTHETIC CHEMOKINE RECEPTOR LIGANDS AND METHODS OF USE THEREOF | INTERMUNE, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004110245-A2 | COMBINATION THERAPY FOR CANCER TREATMENT | INTERMUNE, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040167139-A1 | Methods of treating cancer | INDIANA UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
| WO-2004063036-A1 | SAFETY CONTAINERS FOR BIOLOGICALLY ACTIVE SUBSTANCES AND METHOD FOR PRODUCING SAID CONTAINER | BAXTER HEALTHCARE S.A. (CH) | 2004-07-29 | — | — | WO | disclosed |
| US-20040028607-A1 | Methods of modulating tubulin deacetylase activity | THE J. DAVID GLADSTONE INSTITUTES | 2004-02-12 | — | — | US | disclosed |
| WO-2004010937-A2 | METHOD OF TREATING CANCER | ADVANCED RESEARCH & TECHNOLOGY INSTITUTE AT INDIANA UNIVERSITY (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003099210-A2 | METHODS OF MODULATING TUBULIN DEACETYLASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070009593-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | EGFR 4121/4885KDR 4668/4885BRAF 3138/4885 |
| US-11364298-B2 | Photosensitizing antibody-fluorophore conjugates | CD47, PDCD10, CD2 | EGFR 48/4885KDR 955/4885BRAF 1235/4885 |
| US-11364297-B2 | Photosensitizing antibody-fluorophore conjugates | CD47, PDCD10, CD274 | EGFR 44/4885KDR 1340/4885BRAF 1126/4885 |
| US-20040167139-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | EGFR 4121/4885KDR 4668/4885BRAF 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.